Asterand PLC

It takes time to develop expertise. This realization long encouraged the world's largest pharmaceutical firms to build and maintain in-house intellectual and technical capacities that served as source

They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around t

Despite what a young biotechnology company's bankers will tell them, raising debt ahead of the approval and commercialisation of the company's first product, is rarely a good idea. The rationale, whic

Asterand's chief financial officer, John Stchur has left the company to be replaced by Alan Fishman as interim CFO. Mr Stchur served at Asterand for nine years, most recently negotiating the successfu